Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET

Company Participants

Zack Kubow - Real Chemistry
Richard Miller - President and CEO, Co-Founder
Leiv Lea - Chief Financial Officer
Jeffrey Arcara - Chief Business Officer
James Rosenbaum - Senior Vice President of Research
Ben Jones - Senior Vice President of Regulatory and Pharmaceutical Sciences

Conference Call Participants

Jeff Jones - Oppenheimer
Graig Suvannavejh - Mizuho Securities
Liang Cheng - Jefferies
Rosemary Li - Cantor Fitzgerald

Operator

Good afternoon ladies and gentlemen and welcome to the Corvus Pharmaceuticals' Business Update and Reports First Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode. Following the presentation we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Monday, May 06, 2024.

I would now like to turn the conference over to Zack Kubow of Real Chemistry. Please go ahead.

Zack Kubow

Thank you, operator and good afternoon everyone. Thanks for joining us for the Corvus Pharmaceuticals' first quarter 2024 business update and financial results conference call. On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Jim Rosenbaum, Senior Vice President of Research and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. The executive team will open the call with some prepared remarks, followed by a question-and-answer period.

I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus' annual